Quantifying pharmacologic suppression of cellular senescence:
                        prevention of cellular hypertrophy versus preservation of proliferative








































In cell culture, cellular senescence is usually defined as 
a state of irreversible cell cycle arrest [1, 2]. Hence, 
cellular senescence is sometimes confused with growth 
inhibition. Here we will use the term ‘growth’ as an 
increase in cellular mass, regardless of whether cells 
proliferate or not. Intriguingly, Ras, MEK and serum, 
which stimulate growth-promoting pathways, contribute 
to and facilitate cellular senescence [3-6].  In theory, 
cellular senescence is caused by inappropriate activation 
of growth-promoting pathways, when actual growth is 
impossible [7, 8]. In proliferating cells, growth-
promoting mTOR (Target of Rapamycin) and MAPK 









































cellular mass growth and cell cycle progression. When 
the cell cycle is blocked by either p21 or p16, growth-
stimulation via mTOR leads to cellular senescence [9]. 
Serum withdrawal, PI-3K, mTOR and MEK inhibitors, 
all decreased mTOR activity and prevented permanent 
loss of proliferative potential [10, 11].  The term “per-
manent loss of proliferative potential” means that, even 
when p21 and p16 were shut off, cells cannot resume 
proliferation [12]. Inhibitors of mTOR such as 
rapamycin preserved proliferative potential [9-11]. To 
avoid confusions, we stress that rapamycin does not 
stimulate proliferation, does not abrogate cell cycle 
arrest caused by p21 and does not force cells to by-pass 
cell cycle arrest. Rapamycin converts senescence (an 



























proliferative  potential  (competence)  correlated  with  inhibition  of  S6  phosphorylation  by  rapamycin.  When  p21  was
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condition). It is still unknown whether rapamycin 
suppresses senescence in a dose-dependent manner and 
whether this suppression correlates with the degree of 
mTOR inhibition.  
 
Another common marker of cell senescence is a large 
cell morphology (hypertrophy). Cellular hypertrophy is 
usually measured as a cell diameter. Given that volume 
(or cell mass) is proportional to the cube of diameter, 
then the amount of protein per cell (cell mass) may be a 
more sensitive parameter than cell diameter. For 
example if diameter is increased 2-fold, cell mass is 
increased 8-fold. In theory, cell mass could be estimated 
as an amount of any fluorescent protein such as green 
fluorescent protein (GFP), expressed by a constitutive 
viral promoter such as CMV promoter. If the cell cycle 
is blocked but cells continue to grow in size, then GFP 
should accumulate. Here we tested this prediction. 
Independently from our study, a clone of HT-p21 cells, 
known as p21-9, had been stably transfected with 
CMV-EGFP [13, 14, 15] and thus expresses enhanced 
GFP. We predict that induction of p21 by IPTG should 
increase GFP per cell, as a marker of cellular 
hypertrophy. Given cell-doubling time of 20 hours, 
there should be a 10-14 fold increase in GFP/cell in 3 
days. Here, we confirmed this prediction. We further 
investigated the link between mTOR activity, cellular 
hypertrophy and loss of proliferative potential.  We 
found that preservation of proliferative (competence) 
was the most sensitive marker of mTOR inhibition, 
easily detectable even at concentrations of rapamycin 




Exponential mass-growth precedes senescence 
 
A number of proliferating cells increased exponentially 
(with a doubling time 20-24 h). As previously 
described, induction of p21 by IPTG caused G1 and G2 
arrest [1, 4, 5], completely blocking cell proliferation 
(Figure 1). p21-arrested cells continued to grow in size, 
becoming hypertrophic. Since the cells contained CMV-
driven EGFP, we measured both protein and GFP. Per 
well, amounts of GFP and protein were increased 
almost exponentially with or without IPTG (Figure 2). 
Per cell, amounts of GFP and protein were increased 
only for IPTG-treated (non-dividing) cells (Figure 3).   
For proliferating cells (no IPTG), GFP per cell and 
protein per cell remained constant (Figure 3), because 
mass growth was balanced by cell division. In contrast, 
in IPTG-treated cells, protein/cell and GFP/cell 
increased almost exponentially for 3 days (Figure 3). 
During induction of senescence by IPTG, cellular mass 
continued to increase but was not balanced by cell 
division.  In all cases, protein and GFP correlated 






































































































Although that was not the goal of our study, our data 
can explain how induction of p21 can induce GFP 
without trans-activating CMV promoter: by inhibiting 
cell cycle without inhibiting cell growth. Furthermore, 
the notion that GFP per cell is a marker of hypertrophy 
yields 2 predictions. First, mutant p21 that cannot bind 
CDKs and thus cannot arrest cell cycle will not induce 
GFP. Second, anti-hypertrophic agents such as 
rapamycin will reduce GFP per cell without abrogating 
cell cycle arrest. 
 
Dose dependent suppression of cellular hypertrophy  
    
We next investigated the effects of rapamycin on 
hypertrophy of senescent cells. Cells were induced to 
senesce by IPTG in the presence (+R) or the absence of 
rapamycin. On days 3 and 5 effects of rapamycin on 
cellular hypertrophy were evaluated. By microscopy, 
the anti-hypertrophic effect of rapamycin was the most 
evident at low cell densities (such as 1000 cells per 60-
mm dish) because there was a sufficient space for 
IPTG-treated cells to grow in size in the absence of 
rapamycin (Figure 4). However, we could not reliably 
measure protein levels at such low cell densities. At 
regular cell densities, rapamycin (500 nM) reduced 
cellular hypertrophy by 30% -40% (Figure 5A and data 
not shown). Two markers of hypertrophy (protein/cell 
and GFP/cell) correlated (Figure 5A). The anti-
hypertrophic effect of rapamycin was not statistically 
significant at concentrations of rapamycin below 20 
nM. At first, this was puzzling given that rapamycin 
inhibits the mTOR pathway at low concentrations in 
many cell types. Therefore, we investigated a dose 
response of mTOR inhibition by measuring S6 
phosphorylation, a marker of mTOR activity. In 
agreement with anti-hypertrophic effects, rapamycin 
inhibited S6 phosphorylation at concentrations 20 nM 
or higher, achieving maximal effects at 100 nM-500 nM 
(Figure 5 B). Thus, inhibition of S6 phosphorylation 
and inhibition of hypertrophy correlated, explaining the 
requirements of high concentration (100-500 nM) of 
rapamycin for anti-hypertrophic effects in this particular 













Figure  3.  Cellular  hypertrophy  during  senescence
induction. HT‐p21 cells were grown in 60 mm wells and cell
numbers,  soluble  protein  and  GFP  were  measured  daily.
Closed  bars:  HT‐p21  cells  were  treated  with  IPTG  (+IPTG).
Open bars: Untreated HT‐p21 cells (‐IPTG). Protein per cell and
GFP  per  cell  were  constant  in  proliferating  (‐IPTG)  cells.
















Dose-dependent preservation of cellular competence  
 
Rapamycin preserves proliferative potential in arrested 
cell, meaning that cells can successfully divide when 
the arrest is lifted. But rapamycin does not induce 
proliferation and in contrast can cause quiescence (in 
some cell types). To clearly distinguish the potential to 
proliferate (competence) and actual proliferation, we 
introduce terms competence and incompetence (per-
manent loss of proliferative potential associated with 
cellular senescence). In HT-1080 cells, rapamycin 
preserves competence during cell cycle arrest caused by 








































We have demonstrated previously that rapamycin 
preserved cellular competence (the ability to proliferate 
after p21 is switched off) in IPTG-arrested HT-p21 cells 
[10]. We performed these experiments using rapamycin 
at concentration 500 nM [10], which completely 
inhibited S6 phosphorylation. Here we determined 
whether preservation of competence (PC) correlated 
with inhibition of S6 phosphorylation and the anti-
hypertrophic effect of rapamycin. Cells were treated 
with IPTG and increasing concentrations of rapamycin 
ranging from 0 to 500 nM (Figure 5 C). After 3 days, 
IPTG was washed out, thus allowing the cells to 
proliferate, and after another 5 days cells were counted. 
As expected, the IPTG-treated cells became 
incompetent, whereas rapamycin suppressed 
incompetence (Figure 5 C). Remarkably, preservation 
of competence was detectable at lower concentrations of 
rapamycin than those that inhibited either S6 















































higher sensitivity of a PC-test compared with inhibition 
of hypertrophy may be due to the relative magnitudes of 
the effects (30% inhibition of hypertrophy versus 800% 
PC). Perhaps even a transient inhibition of mTOR 
(missed by immunoblot) detectably increased compe-
tence. Consistent with this explanation, even when 
rapamycin was added with delay, preservation of 
competence was detectable [10].  
 
Exponential proliferation of competent cells  
 
In the presence of IPTG (with or without rapamycin), 
the cells did not proliferate and did not form colonies. 
When IPTG was washed out, 3-5% cells remained 
competent even without rapamycin [10] and Figure 6. 
Colonies grew in size, while the number of colonies was 
almost unchanged (Figure 6). Rapamycin increased a 
number of colonies (a number of competent cells) 
almost 10- fold. We further compared the proliferative 
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IPTG either without or with rapamycin (I/w and I+R/w, 
respectively). In I/w and I+R/w conditions, the number 
of cells started to increase exponentially after 1 day and 
3 days, respectively (Figure 7). After 6 days, both 
curves (I/w and I+R/w) became parallel.  The curve 
“I+R/w” was just shifted to the right on approximately 3 
days (Figure 7). This corresponded to a 10-fold 
difference in an initial number of competent cells, if 
their doubling time was around one day. Noteworthy, 
this also corresponds to the initial difference in the 
number of competent cells as determined by colony 
formation (Figure 6). Also, both in I/w and I+R/w 
conditions, doubling time of the competent cells was 
around 20-24 hours, similar to the proliferative rate of 
the untreated cells.  
 
Reversal of hypertrophy during proliferation of 
competent cells 
 
Rapamycin decreased cellular hypertrophy approxi-
mately 30% in IPTG treated cells (Figure 5A). When 
IPTG and rapamycin were washed out, there was a lag 
period about 24-30 hrs for competent cells to undergo 
first division (supplementary movie will be available 
at). During the lag period, cells grew in size, because 
rapamycin was washed out. Consequently, as measured 
by GFP per cell (Figure 8A), rapamycin-treated cells 


























gure 8A: I/w and I+R/w at day one). Similarly, as 
measured by protein per cell, the cells treated with 
IPTG plus rapamycin become fully hypertrophic at day 
one after wash (data not shown). Despite regaining 
hypertrophy, IPTG+rapamycin-treated cells remained 
competent (Figures 6, 7). This indicates that hyper-
trophy was not a cause of proliferative incompetence in 
IPTG-treated cells. When competent cells divided, GFP 
per cell decreased (Figure 8 B). In agreement, there was 
a marked difference in cell morphology of typical cells 
in both conditions (Figure 9).  Under I/w conditions, 
most of the cells were still large and flat, expressing 
beta-Gal staining. Under I+R/w conditions, 
predominant cells were with a small-cell morphology 
and beta-Gal-negative. These cells formed colonies, 
indicating that they acquired non-senescent morphology 
due to proliferation (Figure 10 C, example 1). In 
contrast, senescent cells that did not resume 
proliferation remained large (Figure 10 C, example 2). 
Competent cells, while proliferating and forming 
colonies, became smaller in size (Figure 10 C, example 
1). Eventually, the average cell size dropped to normal 
levels under I+R/w conditions, coincident with a 
decrease in both the amount of protein/cell and GFP/cell 
coincided (Supplemental Figure  2), indicating that both 
are markers of cellular hypertrophy. Despite reversal of 
hypertrophy and a drop in GFP/cell, the amount of total 
GFP and protein per well increased due to cell 

























Figure  6.  Clonal  proliferation  of  competent  cells.  HT‐p16
cells were plated in 100‐mm plates. The next day, 50 µM IPTG with
or  without  rapamycin,  if  indicated  (RAPA),  was  added.  After  3
days,  the  plates  were  washed  to  remove  IPTG  and  RAPA.  (A)
Photographs. Upper panel: On days 5 and 8 (after IPTG removal),
plates  were  fixed,  stained  and  photographed.  Lower  panel:  On
days 5 and 8 (after IPTG removal), plates were fixed, stained and











































Acting in concert, three conditions can contribute to 
cellular hypertrophy: cell cycle arrest, continuous 
protein synthesis and insufficient autophagy. When the 
cell cycle was blocked by p21, HT-p21 cells grew in 
size almost exponentially for 3 days, eventually 
becoming senescent. In parallel with protein content, 
the amount of GFP (driven by the CMV promoter) per 
cell was increased up to 15-20-fold in senescent cells, 
an increase that may be a marker of cellular 
hypertrophy.   
 
Why cells did not grow in size indefinitely while 
turning into senescent cells? First, cellular growth may 
become counter-balanced by autophagy. This is likely, 
given the increase in beta-Gal staining and vacuo-
larization in senescent cells and the recent finding that 
autophagy is activated several days after senescence 
induction, coincident with spontaneous deactivation of 
the PI-3K/mTOR pathway [16]. We also observed 
dephosphorylation of S6, when IPTG-treated cells 
became terminally-senescent (MS in preparation). Also, 
senescent cells may become compensatory insensitive 

























and  IPTG  plus  Rapa,  respectively.  Open  and  closed  circles: 
























Figure  8.  Loss  of  hypertrophy  during  proliferation  of 








(I+R/w),  respectively.  When  cells  resumed  exponential 




Rapamycin modestly (30-40%) suppressed cellular 
hypertrophy and dramatically (10-fold) increased the 
number of competent (for proliferation) cells.  When 
competent cells were released from p21-induced block, 
they first grow in size for one day (before division) and 
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does not preclude normal mitosis. While dividing and 
proliferating, such cells became progressively smaller. 
This recovery phase is a mirror image of the 
senescence-induction phase, in which cells grow 

















































How can we explain preservation of mitotic competence 
by rapamycin? This unlikely results from the anti-
hypertrophic effect of rapamycin, given that after 
rapamycin removal competent cells ‘catch up’ in size 
with other cells. We suggest that mitotic incompetence 
is not caused by hypertrophy but rather hypertrophy and 
incompetence are independent hallmarks of cellular 
aging. We hypothesize that mitotic incompetence may 
result from cellular hyper-activation during cell cycle 
arrest. Activated mTOR and MAPK pathways may 
force cell cycle progression despite p21-induced arrest, 
causing abortive S-phase entry. In fact, cyclin D1 is 
highly elevated in senescent cells [9] and Rb is depleted 
[17]. In principle elevation of cyclins and depletion of 
Rb may allow p21-arrested cells to enter S-phase, thus 
damaging the cell. Perhaps, premature cell cycle 
progression and mitotic incompetence are two sides of 
the same coin: overactivation of growth promoting and 
mitogen-activated pathways during cell cycle arrest. 
Then unscheduled S phase re-entry might be 
preventable by rapamycin. This hypothesis is under 
investigation. Noteworthy, rapamycin blocks pseudo-
DNA damage response, associated with cellular 
overactivation [18].  Another hallmark of cellular over-
activation in senescent cells is hyper-secretory and pro-
inflammatory phenotype, characterized by production of 
cytokins, mitogens and proteases [19-26]. Needles to 
say, rapamycin is an anti-inflammatory drug and is 
labeled for use (at high doses) as immunosuppressant in 
the clinic. It was suggested that rapamycin as an anti-





washed  and  microphotographs  were  taken  after  additional  3
days. Cells were stained for beta‐Gal. A: I/w; B:  I+R/w.   
 
MATERIAL AND METHODS 
 
Cell lines and reagents.  In HT-p21 cells, p21 
expression can be turned on or off using isopropyl--
thio-galactosidase (IPTG) [14, 15]. HT-p21 cells were 
cultured in DMEM medium supplemented with FC2 
serum. Rapamycin was obtained from LC Laboratories 
and dissolved in DMSO as 2 mM solution and was used 
at final concentration of 500 nM, unless otherwise 
indicated. IPTG and FC2 were obtained from Sigma-
Aldrich (St. Louis, MO). IPTG was dissolved in water 
as 50 mg/ml stock solution and used in cell culture at 
final concentration of 50 µg/ml.  
 




without  drugs  to  allow  proliferation.  (A)  Normal  size  of
proliferating cells. (B) Cellular hypertrophy of senescent cells. (C)
Example 1. Clonal proliferation of competent cells results in loss
of  hypertrophy.  (C)  Example  2.  Cells  that  remained  arrested
remained hypertrophic.  
Immunoblot analysis. Cells were lysed and soluble 
proteins were harvested as previously described [9]. 
Immunoblot analysis was performed using mouse 
monoclonal anti-p21, mouse monoclonal anti-phospho-
S6 Ser240/244 (Cell Signaling, MA, USA), rabbit 
polyclonal anti-S6 (Cell Signaling, MA, USA) and 
mouse monoclonal anti-tubulin Ab as previously 
described [9].  
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Cell counting.   Cells were counted on a Coulter Z1 cell 
counter (Hialeah, FL).  
 
Colony formation assay. Two thousand HT-p21 cells 
were plated per 100 mm dishes. On the next day, cells 
were treated with 50 µg/ml IPTG and/or 500 nM 
rapamycin, as indicated. After 3 days, the medium was 
removed; cells were washed and cultivated in the fresh 
medium. When colonies become visible, plates were 
fixed and stained with 0.1% crystal violet (Sigma).   
Plates were photographed and the number of colonies 
were determined as previously described [9].  
 
SA--Gal staining. Cells were fixed for 5 min in beta-
galactosidase fixative (2 % formaldehyde; 0.2% 
glutaraldehyde in PBS), and washed in PBS and stained 
in -galactosidase solution (1 mg/ml 5-bromo-4-chloro-
3-indolyl-beta-gal (X-gal) in 5 mM potassium 
ferricyamide, 5 mM potassium ferrocyamide, 2 mM 
MgCl2 in PBS) at 37 ºC until beta-Gal staining become 
visible in either experiment or control plates. 
Thereafter, cells were washed in PBS, and the number 
of -galactosidase activity-positive cells (blue staining) 
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cells  were  treated  with  IPTG  plus  500  nM  rapamycin  for  3
days. Then the cells were washed and the cells were incubated
in the fresh medium without drugs. At indicated days, soluble
protein,  GFP  and  cell  numbers  were  measured  per  well.
Protein  (pr)  per  cell  and  GFP  per  cell  were  calculated  and
plotted in arbitrary units.  
  Figure  S1.  Induction  of  p21  by  IPTG.  HT‐p21  cells  were
plated in 6 well plates and treated with IPTG with or without
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